Wall Street’s so-called fear gauge was down Tuesday, as the U.S. stock market staged a broad rally in its first day of trading under the new White House administration. The Cboe Volatility Index was falling around 4.

Goldman Sachs is tapping several executives to lead its prized Wall Street businesses, it said on Tuesday, as part of a management reshuffle less than a week after reporting its biggest quarterly profit in more than three years.

U.S. stocks finished higher on Tuesday as Wall Street wrapped up the first trading day of President Donald Trump's second term in office on a positive note. The Dow Jones Industrial Average rose 537.98 points,

Another engine of value creation for Wall Street that has been slow in recent years is the IPO market — which is also set to pick up.

Wall Street has been seesawing for weeks as traders tear up their forecasts for what the Fed will do with interest rates in 2025. A further easing would boost the U.S. economy and prices for investments, but it could also give inflation more fuel.

Charles Schwab also beat Wall Street’s fourth-quarter earnings estimate and reversed a revenue decline from the year-ago quarter.

Pure-play space stocks flew higher on Tuesday, in a rally described as exuberance about the sector after President Donald Trump’s inauguration.

Bank of America made $6.7 billion of profit in the fourth quarter of 2024, more than doubling earnings from a year earlier and beating analysts’ estimates of $6 billion. The second-largest U.S. lender by assets posted per-share earnings of 82 cents,

Shares of Palantir Technologies (NASDAQ: PLTR) advanced 1,110% during the last two years as the company benefited from strong demand for its artificial intelligence platform. The median target of $39 per share implies 52% downside from its current share price of $80.

Important earnings season ahead as investors look for positive signs that the US economy can continue to be resilient in 2025

JPMorgan shares jumped on the bank's final financial results of 2024, climbing 2.6% before the bell.

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.